Evaluate SLN360 in Participants With Elevated Lipoprotein(a) at High Risk of Atherosclerotic Cardiovascular Disease Events
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 180 participants.
Also called NCT05537571
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 180 participants
- Sponsor
- Silence Therapeutics plc
- Registry
-
NCT05537571
-
- Main results
- Zerlasiran-A Small-Interfering RNA Targeting Lipoprotein(a): A Phase 2 Randomized Clinical Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Australia, Czechia, Denmark, Netherlands, Slovakia, South Africa, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT05537571. Randomized; double masking; primary purpose treatment. Start 2022-12-13 (actual); primary completion 2024-01-11 (actual). Results posted on 2025-07-01.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Evaluate SLN360 in Participants With Elevated Lipoprotein(a) at High Risk of Atherosclerotic Cardiovascular Disease Events
- Condition
- Cardiovascular Diseases
- Condition
- Atherosclerosis
- Condition
- Lipoprotein(a)
- Intervention (Drug)
- SLN360
- Intervention (Drug)
- Placebo
- Lead sponsor
- Silence Therapeutics plc
Record details
- Record id
cardio:ct-nct05537571- Content hash
a8376dc0260711e9e18c3aa3e2916e4c5e6b9831d7dc29687a0c637227c6108d